SPRC

SPRC

USD

SciSparc Ltd. Ordinary Shares

$3.060-0.190 (-5.846%)

リアルタイム価格

Healthcare
バイオテクノロジー
イスラエル

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$3.250

高値

$3.320

安値

$3.060

出来高

0.06M

企業ファンダメンタルズ

時価総額

5.0M

業種

バイオテクノロジー

Israel

取引統計

平均出来高

4.79M

取引所

NCM

通貨

USD

52週レンジ

安値 $1.75現在値 $3.060高値 $37.59

関連ニュース

GlobeNewswire

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model,

もっと見る
N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers
GlobeNewswire

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

TEL AVIV, Israel, Oct. 24, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders

もっと見る
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
GlobeNewswire

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies

もっと見る
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
GlobeNewswire

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model,

もっと見る
N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
GlobeNewswire

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

According to the agreement, SciSparc's pharmaceuticals assets and equity stake in SciSparc Nutraceuticals Inc. are valued at approximately US$11.6 million TEL AVIV, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc

もっと見る
SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio